Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
Summary
Third Opinion Trial Synopsis:
The UNIVERSAL study is trying to find out if a new treatment called ALLO-715, with or without Nirogacestat, is safe and effective for adults with multiple myeloma who have already tried other treatments. They will also look at how the cells in the body react to the treatment and whether it causes an immune response. The treatment will be given after the patients receive certain other medications.
The UNIVERSAL study is trying to find out if a new treatment called ALLO-715, with or without Nirogacestat, is safe and effective for adults with multiple myeloma who have already tried other treatments. They will also look at how the cells in the body react to the treatment and whether it causes an immune response. The treatment will be given after the patients receive certain other medications.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of the UNIVERSAL study is to assess the safety, efficacy, cell kinetics, and immunogenicity of ALLO-715 with or without Nirogacestat in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen of ALLO-647 in combination with fludarabine and/or cyclophosphamide, or ALLO-647 alone.
The purpose of the UNIVERSAL study is to assess the safety, efficacy, cell kinetics, and immunogenicity of ALLO-715 with or without Nirogacestat in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen of ALLO-647 in combination with fludarabine and/or cyclophosphamide, or ALLO-647 alone.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: